Clene Nanomedicine, Inc.
Clene: Revolutionizing treatments for neurodegenerative disease.
Clene: Revolutionizing treatments for neurodegenerative disease.
Clene Nanomedicine, Inc. is a late clinical-stage biopharmaceutical company focused on revolutionizing treatments for neurodegenerative diseases. The company's investigational therapy, CNM-Au8®, targets mitochondrial function and the NAD pathway, reducing oxidative stress and improving central nervous system cells' survival and function. Founded in 2013, Clene is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. Their most recent investment was a $45.10M grant from the National Institutes of Health on 05 October 2023. With a focus on improving mitochondrial health and protecting neuronal function, Clene is dedicated to advancing therapies for neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. Learn more about Clene at www.clene.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $45.10M | 1 | National Institutes of Health | 05 Oct 2023 |
| Post-IPO Debt | $5.00M | 1 |
-logo.jpg){kind=logo}
|
31 Oct 2022 |
| Post-IPO Equity | $10.80M | - | 31 Oct 2022 | |
| Grant | $1.00M | 1 |
|
13 Dec 2021 |
| Post-IPO Equity | $22.40M | 1 |
|
30 Dec 2020 |
No recent news or press coverage available for Clene Nanomedicine, Inc..
We care about your data, and we'd love to use cookies make your experience better.